<DOC>
	<DOCNO>NCT00360412</DOCNO>
	<brief_summary>Patients complete one core trial ( E2007-E044-301 E2007-A001-302 ) meet inclusion/exclusion criterion enrol enter Titration Phase , last 4 week ( week 0-3 ) follow Maintenance Phase , last 52 week ( week 4-56 ) . All patient receive active study drug . During Titration Phase , patient receive E2007 2 mg daily ( o.d . ) 2 week follow 4 mg o.d . 2 week . During Maintenance Phase , patient receive 4 mg o.d . Patients tolerate study drug 4 mg , allow titrate 2 mg . Patients tolerate 2 mg withdrawn study . Patients visit 2 , 4 , 8 , 20 , 32 , 44 , 56 week study entry . In addition , follow-up visit occur 4 week study treatment end ( week 60 ) . A home diary complete patient rate either : 1 . OFF 2 . ON without dyskinesia 3 . ON non-troublesome dyskinesia 4 . ON troublesome dyskinesia 5 . Asleep These entry complete every half hour wake day complete 3 consecutive day follow visit week 4 , 8 , 20 , 32 44 , three day prior visit week 56 60 . At entry study ( week 0 ) week 8 , 20 , 32 , 44 56 , Unified Parkinson 's Disease Rating Scale ( UPDRS ) , Clinician 's Global Impression Change ( CGIC ) Clinical Global Impression Tolerance ( CGIT ) perform .</brief_summary>
	<brief_title>A Study E2007 Adjunctive Therapy Levodopa Treated Parkinson 's Disease Patients With Motor Fluctuations</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Male female patient idiopathic PD fulfil entry criterion either E2007E044301 E2007A001302 complete study include final efficacy visit . Patients eligible withdraw core study prior final efficacy visit reason include lack efficacy . Patients SAEs ongoing possibly probably related study drug , eligible study . Patients ongoing adverse event categorize severe think relate E2007 enter . Patients mild moderate adverse event think relate E2007 enter study investigator considers safe . 1 . Pregnant lactating woman . 2 . Women child bear potential unless infertile ( include surgically sterile ) practice effective contraception ( e.g. , abstinence , IUD barrier method plus hormonal method ) . These patient must negative serum urine BHCG test first study visit . These patient must also willing remain current form contraception duration study . Postmenopausal woman may recruit must amenorrhoeic least 1 year consider nonchild bear potential determined investigator . 3 . Patients past ( within past 5 year ) present history drug alcohol abuse per DSM IV criterion . 4 . Patients past ( within one year ) present history suicidal ideation suicide attempt . 5 . Patients past ( within one year ) present history psychotic symptom require antipsychotic treatment . Patients may take antidepressant medication , however dose must stable 4 week prior baseline visit . Use antipsychotic medication include clozapine quetiapine prohibit even indication movement disorder . 6 . Patients unstable abnormality hepatic , renal , cardiovascular , respiratory , gastrointestinal , haematological , endocrine metabolic system might complicate assessment tolerability study medication . 7 . Patients significantly elevate liver enzyme ( abnormal bilirubin serum transaminase level 1.5 time upper normal limit ) . 8 . Medication know induce enzyme cytochrome P450 3A4 prohibit throughout study . 9 . Current prior treatment ( within 4 week prior entry visit ) tolcapone , methyldopa , budipine , reserpine , seroquel . 10 . Patients condition affect peripheral central sensory system unless related Parkinson 's disease ( mild sensory pain syndrome limit OFF period ) could interfere evaluation symptom cause study drug . 11 . Patients receive plan ( next 12 month ) deep brain stimulation . 12 . Patients condition would make patient , opinion Investigator , unsuitable study . 13 . Patients clinically significant ECG abnormality , include prolonged QTc ( define QTc â‰¥ 450 msec ) . 14 . Patients previous stereotactic surgery ( e.g. , pallidotomy ) Parkinson 's disease plan stereotactic surgery study period . 15 . Patients pergolide April 5 , 2007 .</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>